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PcJygiutrmrtc analogs of folnfe and rclotrd rompoundr wrc rated as inhibits of us&n kinurc 1: r-ZK 11) obtGncd from Xrnopu fucds. The 
inhibitory cnlurcity of the ptcroyl, i-amino-IO-nethyl ptcroyl (the mclhotrcxatc rromaticmoicty), ad *-aminoknzoil dcrivntiba increased 3s the 
number of y~~lutamatcr Irttachcd went from 1~ 7. The nntucc aT the aromatic lc;ld group was ulro itnporfant rincc hcxr-y-ylutumatic rcid bud 
na inhibitory uctivity while the r~lylhcxuylulnlltillc dcrivativcr urr~ Jtrona inhibitors with rclutivr potency ot’ mcthotrcxutc > ptcroyl > p’ 
aminabcnzoit ncid. The inhibition oTCK I1 by m:thotrexutc r-pcntuylut;lm;ltc umrcompctitivc with wscin und showrd un rpprrent K, of 9OflM. 
Folylpolyylutrmatc: Mclhntrcr;rtc: C;lsein kinna II: Xe~r~p~pru /IICI$X: Prcroylply~lutumatc 
1. 1NTRUDtJCTION 
Cascin kinusr II (CK II) is a ubiquitous cukaryotic 
protein kinasc that phosphorylutcs crinc or threoninc 
in chc acidic regions of proteins. This cnzymc has been 
shown to phosphorylatc mnny key cnzyn~rs irivolusd ia 
ccl1 division such as DNA and RNA polymcrascs. to- 
poisomcmsti, and the products of nuclear oncogcncs 
such as myc, myb, jun and fos (for reviews ee [I 2)). In 
addition. CK Ii appnlrs to be regulated uring thr cell 
division cycle and by factors that induce prolifcrotion 
[3,41* 
The work of the laboratories of Pinna [5] and Krcbs 
[6] has dcmonscrnccd that CK II phosphorylutes protein 
scqucnccs in which the acceptor scrinc or thrconinc is 
followed towards the carboxyl end by scvcral acidis 
residues uch as aspartic or glutamic acids or previously 
phosphorylatcd amino acids. The affinity of CK 11 for 
these polyanionic scqucnccs explains the very potcnc 
inhibitory effect of hcparin [7], nucleic acids [8,9], and 
Polyglutamic and polyaspartic pcpcidcs [lo] on this cn- 
zyms. 
important cocnzymc cctrahydrofolncc is prcscnt in the 
ccl1 as a mixture of polyglutamated dcrivativcs that con- 
tain an average of 4 to 7 residues of glutumic acid at= 
t&cd to the tctrahydrofolutc moiety by amide bonds 
involving their y-carboxyl group [ 131. 
Thr demonstration that thtso polyglutamatc dcriva- 
tives constitucc the true physiological substrates of the 
cn;rymcs involved in one-carbon metabolism [14] has 
added imporcancs to the study of chcsc ompounds. In 
addition, the finding that mcthotrccxatc. a w&known 
cancer chcmothcrapy drug used to block folatc func- 
tions, is also polyglucamatcd in the ccl1 [I$]. has also 
increased the interest in determining the cffc~ts that 
chess derivatives might have on cellular mctnbolisma 
In this communication WC report that folotc and 
mcthotrcxotc y-polyglutarnatcs CUF strongly inhibit CK 
II purified from Akropu.s h~k Tht inhibitory oapacity 
of chcsc ompounds is influenscd both by the length of 
chc y-glutamate substitution as well as by the nacurc of 
chc folatc analog moiety that is chemically attached to 
thcsc polyanionic dcrivativcs. 
Hovrcvcr. the polyanionic nature of the compounds 
is not the only factor that influences the potency of CK 
II inhibitors. Recent. evidence has demonstrated that the 
prcscncc of the phcnolic side chain of tyrosinc in cope- 
lymcrs of glutamic acid and tyrosinc greatly enhances 
the capacity of these compounds to inhibit CK II 
[I 1,12]. 
2, MATERIALS AND METMOIX 
i. t t Prcjwuliorl of CUl4l kilmsc Ii 
CIvtiricrr wcrc obtained by surgery from adult fcnralc A: !urt-is. S~agc 
5 and 6 oocytcs and nuclei wcrc prcparcd PS described by Duaio and 
Koidc [IS]. Hi$lly purified oocy(c SK II was isolntcd from X. Iurvk 
oocytc nuclei by chromalogruphy otr DEAE-Scphiadcx and 
phosphoccllulosc columns [ 161. 
For a number of years it has been known that the 
(brm~ardwcc uddrcss: 1,E, Allcndc, Dcporlnmcnto dc Dioquimic& 
Facultad dc Mcdicinu, Sasilln 70O86. bntiugo 7, Chile. FW (56) (2) 
737 6320. 
2.2. Assay uf the uclivity o/cuscln kinarr II 
Reactions were carried out in il final volume of 50~1 cuntnining 50 
FM HEPES. pi-l 7.8; I80 mM KSI. 7 mM MgSI,: 0.5 mM dilhiolhrci- 
tol, and 100 PM [p’V]ATP WO-1000 cpm/pmol), In addition. the 
assays included purified SK lf (20-30 U/ml [16]1. 5.0 mghl of’dcs- 
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Fig. I. The structure of~~nmino-l0~mctt~yl-ptcroyl~i-~~~lt~t~t~~~tic 
acid [mctnatrcxutc n70na-7-&m1nu1tc). 
phosphorylutcd cnsin #ad the rpccificd t~n~~~nt of the falatc nnulo~ 
inhibitor. The rtittction wias sfnrtcd by addition of the enzyme end 
incubtttionr wcrc carried out II 3O.C far IO min. The reaction wc’11~ 
fcrminufcd by removal af an itliquot to t 2 x I cm Wbnltnttn I%1 
phosphoccllu!orc pnpcr which was immcncd in 75 mM pba~pharie 
acid, wurlrcd 3 tinrn in the ritlrnc ncid. dried end counted. 
Vnluti wporrrd huvc btcn eorrccfcd for controls run witlr heat- 
dcnaturcd cnzymc. All nsst~yr wcrc pcrformcd in duplicntc and ttrc 
rcprclcntativc of 21 cupcrimsnt5, 
All foIntcqolyplutumntc dcrivotivcr nnd the hurt-y-ylutom;rtc wcrc 
purchtlrrd from B. Schircks Laborntoric~. Swilxcrlnnd. All llrc other 
motcrialr wcrc obtnincd from Sigm;l Chcntiful Co, 
3. RESULTS AND DISCUSSION 
Fig. 1 shows the structure of Qomino N-lO-meth- 
ylptcroyl di-y-t-glutamate as an cxamplc of the struc- 
cure of the compounds used in these studies. 
The results prcscntcd in Fig. 2 show the rise in the 
potency in the inhibition of X. kuc~is CK II by mctho= 
trczace derivatives that contain increasing numbers of 
y-glutamic acid residues. It is clear from thcsc results 
that the elongation of the y-glutamate polymer signifi- 
cantly raises their inhibitory capacity. The f, value of 
the l~cptaglutumntc derivative is approximately S-fold 
lower than that of the diglutamatc ompound (0.36 mM 
vs. 2 mM). 
Similar cxpcrimcnta were performed with ptcroyl and 
p-aminobcnzoyl dcrivntivcs containing diffcrcnt lengths 
of y-polygiutnmate chains (not shown). The results ob. 
rained WCPC qualitatively similar in the sense lhat an 
increasing number of glutomates resulted in stronger 
inhibitory compounds. 
However, there arc some interesting differences in the 
inhibitory capacity depending on the nature of rhc fo- 
late analog head group. Fig. 3 shows a comparison of 
the cffeet on the activity of CK II of three different 
derivatives all containing hcxa-y-glutamate chains, The 
figure also includes the effect of hexa-y-glutamate i self. 
Analysis of these results demonstrates thar hexa-y-&u- 
tamatc hits no detcctrrbIc inhibitory capacity, a finding 
Fig. 2, The inhibitory cl%!ct on CK If of wriour; conscntrnlions of 
whotrcxatc poly&mtmstcx with diffcrcnt rt mbcrr of 7glutumnte 
rcsiduts. The activity of CK II W;III mca~ufp~ 2s dcrcribed in &ion 
2. The vahc far ldO% nrtivity in the nbeacc 21 inhibitor was approx- 
imntcly 32.500 cpm of j:P incorportttcd into ckscin in IO min which 
corrcspondr WI 4.06 pmolmmin incorporated. The rymbulr corrcrpond 
to dcrivnfivcr af mcthotrcxitte containing: (01 dim7qlutttmntc; (a) tri- 
y-&ilximntc; (a) hcxu-y-glutumntc end (D) hcptr-7.&nnm.rte~ 
which is in tigrccmcnt with the report by Pinna’s labora- 
tory on the very low inhibitory capacity c? pentad- 
glutamatcs [lo], The womtic head group thcrtlare 
plays a key role in determining the inhibitory capacity 
of the hcxaglutamntc with the relative potency of the 
compounds being: 4-amino N-10 ptcroyl > ptcro$ > 
p-nminobcnroyl. 
The mechanism of inhibition of the mcthotrr::ttte 
with S additional y-glutamate was assayed by rrnaiy7* 
ing its effect on the kinetic parameters of the enzyme by 
I 1 I 
0.5 I 5 
t-toxoglutomote Derirotiwee tmM 1 
Fig. 3, The inhibixry cffcct 011 CK II of diffcrcnt conccntrtttionl of 
Iicxcl~y~glutuniulc:;. Tbc nssny of CK II wus Crtrricd out n5 dcscrilxd 
in section 2. Thr! G.I!:JC of lOCt% nctlvity in the abscncc of inhibitor was 
upproximatrly 3t).5t10 cptn of IV incorporated into cttosin in thr lc 
min reaction time. ‘This corresponds to 3.8 pmollmin incorporat:d. 
The itlhibitora tcstc:l wcrc: (m) hcxn-yq#tamtttc: (0) ~+nitrobonzoyl- 
hcxa-~glutttmntc: (u) ptcroyl-bcxil.y-plut~matc; and (6) 4.amino-IO- 
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Fig. 4. The cfikc~ of mcthalrcxntc pcnla-y-ylufamalc on the vclochy 
of the CK 11 reaction mcarurcd with different cascin eonccnlralion?+ 
The assays wcrc carried out as dcrcribcd in scclion 3 cxccpl for lhc 
rpccifwl cnscin conccwallonr. The amount or’ ~hc mctholrcxatc 
pcnia-yqlutz.trnalc (~~~mino~IO.mcthyl.g~croyl~l~c~~~~~lulamrtc) 
uacd in each curve was PS follows: (0) none; (a) 50pM: (e) IO0 PM: 
(0) 200pM. The standard dcviarion ol’ the vrlucs is indicalcd. 
using diffcrcnt concentrations of cascin us a substrate. 
The results obtained arc shown in Fig. 4. It is clear that 
this methotrcxatc derivative is a compctitivc inhibitor 
of cnscin. o protein substrate of coscin kinasc If. The 
apparent Ki atculutcd from thcsc studies is of 90 PM. 
while similar studies carried out with p-uminobcnzoyl- 
tri-y-glutamate (not shown) produced an apparent h’i of 
1.7 mM. Thcsc inhibitory activities can bc compared 
with those of synthetic ordsrcd prptidcs such as tyr r tyr 
* (~Iu),.~ which has an apparent iii of Ct.15 mM (Tc!!cz 
et at., in preparation). 
The results prcscntcd above have demonstrated that 
naturally occurring and pharmacologically active fototc 
potyglutamntc dcrivatcs have. a significant capacity to 
inhibit CK II. This capacity is influcnccd both by the 
nature of the aromatic head group as WC!! as by the 
length of the y-polyglutamatc chain. The influcncc of 
the substituted benzene ring and potycyclic structures of 
these derivatives i  noteworthy in relation to the prcvi- 
ous findings that the prcscncc of tyrosinc greatly in- 
creases the inhibitory capacity of polygtutnmic acid 
peptidcs [11,12]. 
The pirysialogical rclcvancc of this inhibitory capac- 
ity camlot bc established by the present study, The con- 
centrations of the potygtutamates required for signifi- 
cant inhibition in the in-vitro assays used hcrc is an 
order of magnitude higher than the concentrations of 
the folutc dcrivativcs known to exist in mammalian cclts 
which are of the order of 15-35 AM [17]. Thcsc: iiri(ci* 
Vuluco agree WC!! with those found for mcthotrcxatc 
taken up by cclts in culture [la]. However. since thcsc 
assays WCC cxricd out with high consentrations of co- 
scin and the inhibition is compctitivc. it is possible that 
physiological pro&in substrates of CK II might be at 
tow enough eoncsntrations toschicvc signifisant inhibi= 
tion by the folylpolyglutamutcs prcscnt in cells, It is also 
known that an important fraction of thcsc folatc dcriv- 
ativcs is bound to dchydrofolotc rcductasc undo rn- 
vivo conditions [!9]. It is possible that the protcin- 
bound potygtutumotc dcrivativcu may have considcm- 
bIy greater inhibitory power for CK It than the free 
compounds that WC have studied. 
drkaacc‘/~~~xrtjilml~: We grtitcfully ockno~lcdgc~hc rrimulation by Dr. 
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